Octant Bio Appoints Industry Veteran Mark Murcko as Strategic Advisor and Board Member
Relay Therapeutics, Inc. (RLAY)
Company Research
Source: Business Wire
Murcko brings over 30 years of chemistry development in biotech experience to the synthetic biology startup EMERYVILLE, Calif.--(BUSINESS WIRE)--Today, Octant, a therapeutics company integrating novel high-throughput experimental technologies with computation to solve complex challenges in drug discovery, announced the appointment of Mark Murcko as Strategic Advisor and Board Member. Murcko brings over three decades of industry experience, having been at the center of many transformational biotech efforts, most recently as founding CSO and Board Member of Dewpoint Therapeutics. Murcko is working closely with the company to scale Octant to its next phase of growth and further develop its chemistry platform.This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211014005238/en/Mark Murcko (Photo: Business Wire)“We have been working with Mark for over a year as a Board Member and are thrilled to share that he’s now working with us
Show less
Read more
Impact Snapshot
Event Time:
RLAY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLAY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLAY alerts
High impacting Relay Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLAY
News
- Relay Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
- Relay Therapeutics: Platform More Important Than Programs [Seeking Alpha]Seeking Alpha
- Relay Therapeutics, Inc. (NASDAQ: RLAY) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.MarketBeat
- Relay Therapeutics to Participate in Three Upcoming Investor ConferencesGlobeNewswire
- Relay Therapeutics Full Year 2023 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
RLAY
Earnings
- 2/22/24 - Beat
RLAY
Analyst Actions
- 2/22/24 - Stifel
RLAY
Sec Filings
- 3/29/24 - Form 4
- 3/29/24 - Form 4
- 3/29/24 - Form 4
- RLAY's page on the SEC website